|Articles|April 1, 2016
- Pharmaceutical Executive-04-01-2016
- Volume 36
- Issue 4
Pharmaceutical Executive, April 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 10 years ago
Closing the Gaps in Drug Chain of Custodyabout 10 years ago
Data Unleashed: Cooperation Among Competitorsabout 10 years ago
Raising the Stakes On Value-Based Pricingabout 10 years ago
The Diversity Dearth in Pharmaabout 10 years ago
Information in Action: A Conversation with Barbara Lopez Kunzabout 10 years ago
R&D Model Mixes Compassion, Calculationabout 10 years ago
Pressure Builds to Revamp Off-Label Marketing Rulesabout 10 years ago
Drug Compounding: A Cause and Cure for High Drug Prices?about 10 years ago
The Odd Coupleabout 10 years ago
Country Report: EgyptAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
2
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5